Protective effect of puerarin against myocardial reperfusion injury. Myocardial metabolism and ultrastructure.
To ascertain the beneficial effect of puerarin on the myocardium against reperfusion injury, studies on myocardial metabolism and ultrastructure were made. Twelve dogs divided into two equal groups were placed on moderate hypothermic cardiopulmonary bypass, and their hearts were subjected to 140 minutes cold cardioplegic arrest and 60 minute reperfusion. In the control group, the hearts were perfused with crystalloid cardioplegic solution (CPS) every 20 minutes during arrest. In the treated group, the hearts received CPS containing puerarin (2 mg/kg). Myocardial oxygen consumption, lactate production, creatine phosphokinase (CPK) release, water content and ultrastructural alterations were determined before ischemia, during cardiac arrest and at reperfusion. The results showed that intermittent infusion of CPS containing puerarin significantly decreased myocardial lactate production during ischemia, as well as myocardial oxygen consumption, CPK release and water content during reperfusion. Under electronmicroscopy, the degree of ischemic damage judged by a scoring method was less pronounced in the puerarin group than in the control. The authors conclude that puerarin has protective effects on the function of hearts that have undergone long periods of arrest and reperfusion.
Fan
L L
LL
Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing.
Sun
L H
LH
Li
J
J
Yue
X H
XH
Yu
H X
HX
Wang
S Y
SY
Dong
S Q
SQ
D000818:Animals; D002314:Cardioplegic Solutions; D004285:Dogs; D006324:Heart Arrest, Induced; D007529:Isoflavones / Q000627:therapeutic use*; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control*; D009206:Myocardium / Q000378:metabolism* / Q000648:ultrastructure*; D010101:Oxygen Consumption; D014665:Vasodilator Agents / Q000627:therapeutic use*
D002314:Cardioplegic Solutions; D007529:Isoflavones; D014665:Vasodilator Agents; C033607:puerarin